Shanrong Biotechnology Corp.
SRBT
$0.3216
-$0.3284-50.52%
| Weiss Ratings | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 9.68 | |||
| Price History | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -32.29% | |||
| 30-Day Total Return | -57.68% | |||
| 60-Day Total Return | 28.64% | |||
| 90-Day Total Return | -33.69% | |||
| Year to Date Total Return | 235.00% | |||
| 1-Year Total Return | -59.74% | |||
| 2-Year Total Return | -48.75% | |||
| 3-Year Total Return | -50.52% | |||
| 5-Year Total Return | 14.04% | |||
| 52-Week High % Change | -91.60% | |||
| 52-Week Low % Change | 242.13% | |||
| Price | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.83 | |||
| 52-Week Low Price | $0.09 | |||
| 52-Week Low Price (Date) | Aug 05, 2024 | |||
| 52-Week High Price (Date) | Feb 04, 2025 | |||
| Valuation | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 155.93K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.32 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 310-359-6895 | |||
| Address | 9350 Wilshire Boulevard Beverly Hills, CA 90212 | |||
| Website | -- | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -368.98% | |||
| Profit Margin | -383.30% | |||
| Management Effectiveness | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -1,026.61% | |||
| Return on Equity | -- | |||
| Income Statement | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.32M | |||
| Total Revenue (TTM) | 1.32M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 1.32M | |||
| EBITDA (TTM) | -4.85M | |||
| EBIT (TTM) | -4.89M | |||
| Net Income (TTM) | -5.08M | |||
| Net Income Avl. to Common (TTM) | -5.08M | |||
| Total Revenue Growth (Q YOY) | -57.40% | |||
| Earnings Growth (Q YOY) | -295.70% | |||
| EPS Diluted (TTM) | -15.67 | |||
| EPS Diluted Growth (Q YOY) | -1,029.60% | |||
| Balance Sheet | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 30.90K | |||
| Cash Per Share (Q) | $0.09 | |||
| Total Current Assets (Q) | 127.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -3.98M | |||
| Current Ratio (Q) | 0.031 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 4.05M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -3.98M | |||
| Cash Flow | SRBT - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 0.00 | |||
| Cash from Financing (TTM) | 756.70K | |||
| Net Change in Cash (TTM) | -30.70K | |||
| Levered Free Cash Flow (TTM) | 667.40K | |||
| Cash from Operations (TTM) | -787.40K | |||
